Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 +/- Famitinib in Advanced or Metastatic NSCLC
NCT04699968Phase 2Withdrawn
- Sponsor
- Hengrui
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules, Fc-Fusion Proteins
01
Overview
Phase 2, randomised, open-label trial of retlirafusp alfa and famitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hengrui. Primary endpoint: Objective Response Rate at 1 year. Planned start Jan 2021; status: withdrawn.
02
Drugs
retlirafusp alfafamitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04699968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699968.